Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 10 |
| List of Tables | 10 | 1 |
| List of Figures | 11 | 1 |
| Introduction | 12 | 1 |
| Global Markets Direct Report Coverage | 12 | 1 |
| Diabetic Nephropathy Overview | 13 | 1 |
| Therapeutics Development | 14 | 2 |
| Pipeline Products for Diabetic Nephropathy Overview | 14 | 1 |
| Pipeline Products for Diabetic Nephropathy Comparative Analysis | 15 | 1 |
| Diabetic Nephropathy Therapeutics under Development by Companies | 16 | 3 |
| Diabetic Nephropathy Therapeutics under Investigation by Universities/Institutes | 19 | 1 |
| Diabetic Nephropathy Pipeline Products Glance | 20 | 4 |
| Late Stage Products | 20 | 1 |
| Clinical Stage Products | 21 | 1 |
| Early Stage Products | 22 | 1 |
| Unknown Stage Products | 23 | 1 |
| Diabetic Nephropathy Products under Development by Companies | 24 | 3 |
| Diabetic Nephropathy Products under Investigation by Universities/Institutes | 27 | 1 |
| Diabetic Nephropathy Companies Involved in Therapeutics Development | 28 | 42 |
| AbbVie Inc | 28 | 1 |
| Ampio Pharmaceuticals, Inc. | 29 | 1 |
| Antisense Therapeutics Limited | 30 | 1 |
| Araim Pharmaceuticals, Inc. | 31 | 1 |
| Arena Pharmaceuticals, Inc. | 32 | 1 |
| Astellas Pharma Inc. | 33 | 1 |
| AstraZeneca Plc | 34 | 1 |
| Bayer AG | 35 | 1 |
| BiOrion Technologies B.V. | 36 | 1 |
| Boehringer Ingelheim GmbH | 37 | 1 |
| Cellmid Limited | 38 | 1 |
| ChemoCentryx, Inc. | 39 | 1 |
| CSL Limited | 40 | 1 |
| Daiichi Sankyo Company, Limited | 41 | 1 |
| Dimerix Bioscience Pty Ltd | 42 | 1 |
| Dong Wha Pharma Co., Ltd. | 43 | 1 |
| Dynamis Therapeutics, Inc. | 44 | 1 |
| Eli Lilly and Company | 45 | 1 |
| Galectin Therapeutics, Inc. | 46 | 1 |
| GenKyoTex S.A. | 47 | 1 |
| Gilead Sciences, Inc. | 48 | 1 |
| GlaxoSmithKline Plc | 49 | 1 |
| Glucox Biotech AB | 50 | 1 |
| GNI Group Ltd. | 51 | 1 |
| Islet Sciences, Inc. | 52 | 1 |
| Jenrin Discovery, Inc. | 53 | 1 |
| Johnson &Johnson | 54 | 1 |
| Mallinckrodt Plc | 55 | 1 |
| Mesoblast Limited | 56 | 1 |
| Mitsubishi Tanabe Pharma Corporation | 57 | 1 |
| MorphoSys AG | 58 | 1 |
| Noxxon Pharma AG | 59 | 1 |
| Omeros Corporation | 60 | 1 |
| Otsuka Holdings Co., Ltd. | 61 | 1 |
| PhytoHealth Corporation | 62 | 1 |
| ProMetic Life Sciences Inc. | 63 | 1 |
| Serodus ASA | 64 | 1 |
| Takeda Pharmaceutical Company Limited | 65 | 1 |
| Theravance Biopharma, Inc. | 66 | 1 |
| Tobira Therapeutics, Inc. | 67 | 1 |
| Vascular Pharmaceuticals, Inc. | 68 | 1 |
| Vicore Pharma AB | 69 | 1 |
| Diabetic Nephropathy Therapeutics Assessment | 70 | 12 |
| Assessment by Monotherapy Products | 70 | 1 |
| Assessment by Target | 71 | 3 |
| Assessment by Mechanism of Action | 74 | 4 |
| Assessment by Route of Administration | 78 | 2 |
| Assessment by Molecule Type | 80 | 2 |
| Drug Profiles | 82 | 123 |
| 11-RVIVIT Drug Profile | 82 | 1 |
| A-717 Drug Profile | 83 | 1 |
| Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology Drug Profile | 84 | 1 |
| APD-371 Drug Profile | 85 | 1 |
| APX-115 Drug Profile | 86 | 1 |
| ASP-8232 Drug Profile | 87 | 1 |
| ATL-1103 Drug Profile | 88 | 7 |
| atrasentan hydrochloride Drug Profile | 95 | 2 |
| baricitinib Drug Profile | 97 | 7 |
| BI-703704 Drug Profile | 104 | 1 |
| BOT-191 Drug Profile | 105 | 1 |
| C-21 Drug Profile | 106 | 2 |
| canagliflozin Drug Profile | 108 | 7 |
| CCX-140 Drug Profile | 115 | 4 |
| cenicriviroc mesylate Drug Profile | 119 | 7 |
| cibinetide Drug Profile | 126 | 3 |
| corticotropin Drug Profile | 129 | 2 |
| CS-3150 Drug Profile | 131 | 2 |
| CSL-346 Drug Profile | 133 | 1 |
| Cyndacel-M Drug Profile | 134 | 1 |
| danazol Drug Profile | 135 | 4 |
| DMX-250 Drug Profile | 139 | 1 |
| DT-23552 Drug Profile | 140 | 1 |
| DW-1029M Drug Profile | 141 | 1 |
| DYN-12 Drug Profile | 142 | 2 |
| emapticap pegol Drug Profile | 144 | 2 |
| finerenone Drug Profile | 146 | 2 |
| GKT-136901 Drug Profile | 148 | 1 |
| GKT-831 Drug Profile | 149 | 3 |
| GRMD-02 Drug Profile | 152 | 10 |
| GW-610742 Drug Profile | 162 | 1 |
| IP-9 Drug Profile | 163 | 1 |
| JD-5037 Drug Profile | 164 | 1 |
| JNJ-39933673 Drug Profile | 165 | 1 |
| MG-132 Drug Profile | 166 | 1 |
| Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications Drug Profile | 167 | 2 |
| MOR-107 Drug Profile | 169 | 1 |
| MPC-300IV Drug Profile | 170 | 4 |
| MT-3995 Drug Profile | 174 | 1 |
| Nephrilin Drug Profile | 175 | 1 |
| Orbcel-M Drug Profile | 176 | 1 |
| oxypurinol Drug Profile | 177 | 1 |
| PBI-4050 Drug Profile | 178 | 5 |
| PBI-4547 Drug Profile | 183 | 1 |
| PHN-033 Drug Profile | 184 | 1 |
| pirfenidone Drug Profile | 185 | 1 |
| probucol Drug Profile | 186 | 1 |
| selonsertib Drug Profile | 187 | 1 |
| SER-150 Drug Profile | 188 | 3 |
| Small Molecule to Inhibit NOX-4 for Diabetic Nephropathy Drug Profile | 191 | 1 |
| Small Molecules for Diabetic Nephropathy Drug Profile | 192 | 1 |
| Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy Drug Profile | 193 | 1 |
| Small Molecules to Target O2 Radical and HMGCR for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders Drug Profile | 194 | 2 |
| SP-20202 Drug Profile | 196 | 1 |
| TAK-272 Drug Profile | 197 | 1 |
| TBE-31 Drug Profile | 198 | 1 |
| TD-0714 Drug Profile | 199 | 2 |
| VPI-2690B Drug Profile | 201 | 1 |
| VS-105 Drug Profile | 202 | 1 |
| XRX-108 Drug Profile | 203 | 1 |
| XRX-221 Drug Profile | 204 | 1 |
| Diabetic Nephropathy Dormant Projects | 205 | 3 |
| Diabetic Nephropathy Discontinued Products | 208 | 1 |
| Diabetic Nephropathy Product Development Milestones | 209 | 10 |
| Featured News &Press Releases | 209 | 1 |
| Jun 20, 2016: Serodus announces that the first patient is randomized into the second cohort of the SER150 Ph IIa study in Diabetic Nephropathy | 209 | 1 |
| Jun 01, 2016: Serodus announces initiation of second cohort in Ph2a study of SER150 in Diabetic Nephropathy | 209 | 1 |
| May 13, 2016: Serodus announces positive opinion from Data Safety Monitoring Board on SER150 Ph2a study | 209 | 1 |
| Mar 09, 2016: Theravance Biopharma Announces Positive Results Including Biomarker Data From Phase 1 Study of TD-0714, an Inhibitor of Neprilysin | 210 | 1 |
| Feb 03, 2016: Serodus announces completion of patient enrollment of the first cohort in Phase 2a clinical trial of SER150 in patients with Diabetic Nephropathy | 211 | 1 |
| Dec 15, 2015: Lopez McHugh files Invokana Lawsuit Alleging Diabetic Ketoacidosis Injury | 212 | 1 |
| Dec 09, 2015: SERODUS appoints scientific advisors for development program in diabetic nephropathy (SER150) | 212 | 1 |
| Dec 08, 2015: Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-0714, an Inhibitor of Neprilysin | 213 | 1 |
| Nov 05, 2015: ChemoCentryx Highlights CCX140 Phase II Diabetic Nephropathy Trial Results at American Society of Nephrology Annual Meeting | 214 | 1 |
| Oct 13, 2015: Theravance Biopharma Submits Investigational New Drug Application for TD-0714, an Inhibitor of Neprilysin | 214 | 1 |
| Sep 09, 2015: Genkyotex Announces Top-Line Results of Phase 2 Clinical Program | 215 | 1 |
| Aug 31, 2015: Bayer Expands Finerenone Clinical Development Programme with Three Phase III Studies in Patients with Chronic Heart Failure and Patients with Diabetic Kidney Disease | 216 | 1 |
| Aug 13, 2015: Serodus announces randomization of first patients in Phase IIa clinical trial of SER150 in patients with Diabetic Nephropathy | 217 | 1 |
| Aug 10, 2015: ANP Licensing Partner for ATL1103 Cortendo Files Prospectus | 217 | 1 |
| Jun 15, 2015: Serodus Receives Approval Of Clinical Trial Application For Ser150 In Diabetic Nephropathy | 217 | 2 |
| Appendix | 219 | 2 |
| Methodology | 219 | 1 |
| Coverage | 219 | 1 |
| Secondary Research | 219 | 1 |
| Primary Research | 219 | 1 |
| Expert Panel Validation | 219 | 1 |
| Contact Us | 219 | 1 |
| Disclaimer | 220 | 1 |